Hvivo (HVO) RNS Announcements

Add to Alert list
Date Time Source Announcement
18 Jul 2025 07:00 AM
RNS
Directorate Change
09 Jul 2025 07:00 AM
RNS
Notice of Trading Update
01 Jul 2025 04:04 PM
RNS
Holding(s) in Company
30 Jun 2025 07:00 AM
RNS
Positive results from client Phase 2b field study
05 Jun 2025 01:00 PM
RNS
Result of AGM
02 Jun 2025 07:00 AM
RNS
Director/PDMR Shareholding
30 May 2025 07:00 AM
RNS
Trading update
29 May 2025 07:00 AM
RNS
Appointment of Independent Non-Executive Director
12 May 2025 07:00 AM
RNS
Annual Report, Notice of AGM & Directorate Change
10 Apr 2025 07:05 AM
RNS
Exercise of Options
10 Apr 2025 07:00 AM
RNS
Final results
26 Mar 2025 01:51 PM
RNS
AIM Rule 17 and Schedule 2(g) Update
21 Mar 2025 07:00 AM
RNS
Notice of Results
07 Mar 2025 07:00 AM
RNS
Director/PDMR Shareholding
27 Feb 2025 07:00 AM
RNS
Acquisition of Cryostore for up to £3.2m
17 Feb 2025 07:00 AM
RNS
£2m hMPV characterisation study contract
05 Feb 2025 07:00 AM
RNS
Shionogi reports positive RSV trial results
03 Feb 2025 07:00 AM
RNS
RSV contract signed with Inhalon Biopharma
31 Jan 2025 01:24 PM
RNS
Holding(s) in Company
31 Jan 2025 07:00 AM
RNS
Holding(s) in Company
29 Jan 2025 07:01 AM
RNS
Acquisition: two Clinical Research Units from CRS
29 Jan 2025 07:00 AM
RNS
Trading update
27 Jan 2025 07:00 AM
RNS
LOI signed for Phase 3 Whooping Cough trial
21 Jan 2025 07:00 AM
RNS
£3.2m hLAB project
14 Jan 2025 07:00 AM
RNS
Holding(s) in Company
13 Jan 2025 07:00 AM
RNS
hMPV challenge model update
12 Dec 2024 07:00 AM
RNS
COVID-19 study published in Nature Communications
10 Dec 2024 07:00 AM
RNS
£11.5m RSV contract and notice of trading update
19 Nov 2024 07:00 AM
RNS
Holding(s) in Company
06 Nov 2024 07:00 AM
RNS
Holding(s) in Company
05 Nov 2024 07:00 AM
RNS
Presentation at Jefferies London Healthcare Conf
11 Oct 2024 07:00 AM
RNS
Long Term Incentive Plan/ PDMR Notification
07 Oct 2024 07:00 AM
RNS
Positive results from RSV human challenge trial
30 Sep 2024 07:00 AM
RNS
Launch of full suite of hLAB standalone services
24 Sep 2024 07:00 AM
RNS
Holding(s) in Company
17 Sep 2024 07:00 AM
RNS
Holding(s) in Company
13 Sep 2024 07:00 AM
RNS
Holding(s) in Company
10 Sep 2024 07:00 AM
RNS
Interim results
05 Sep 2024 07:00 AM
RNS
Holding(s) in Company
20 Aug 2024 07:00 AM
RNS
Notice of results
06 Aug 2024 03:07 PM
RNS
Holding(s) in Company
05 Aug 2024 07:00 AM
RNS
Euronext cancellation
24 Jul 2024 01:55 PM
RNS
Holding(s) in Company
23 Jul 2024 02:48 PM
RNS
Director/PDMR Shareholding
17 Jul 2024 07:01 AM
RNS
Holding(s) in Company
17 Jul 2024 07:00 AM
RNS
Trading update
08 Jul 2024 07:00 AM
RNS
Holding(s) in Company
03 Jul 2024 02:48 PM
RNS
Holding(s) in Company
02 Jul 2024 07:02 AM
RNS
Change of registered address
02 Jul 2024 07:01 AM
RNS
Capital Markets Day & Notice of trading update

hVIVO is a contract research organization that conducts human challenge clinical trials for respiratory and infectious disease vaccines and therapeutics:

hVIVO offers services such as challenge trials, assay development, field trial bio-logistics, cell based assays, molecular services, compound efficacy and VRM, and biomarker analysis.

Formerly known as Retroscreen, hVIVO was renamed in 2015 when it went public on the London Stock Exchange.

hVIVO has a portfolio of 11 human challenge models, with more models in development. Their portfolio includes models for influenza, respiratory syncytial virus, human rhinovirus, asthma, COPD, cough, malaria, COVID-19, and hMPV.

hVIVO share price launched at 33p in 2012.

UK 100